National health programs
Capability should stay where it is built.
NGB is structured to help a country build its own clinical research and biomedical capability, and to leave the scientific leadership, the intellectual property, and the trained investigators with the institutions that host them. We are built to work in both directions: connecting a national health system to international science, and international science to capability it cannot otherwise reach.
We are a nonprofit corporation with no shareholders. There is no mechanism by which value taken from a national program could reach a private owner, because there is no private owner. That is a matter of structure, not of goodwill.
What the bridge carries
A bridge is only useful if traffic moves both ways.
A country entering international science is usually offered one direction of travel: its patients, its sites, its data. The return traffic is what determines whether the arrangement builds anything.
Into the country
Multicentre protocols
Participation as a full investigator site, with a role in study design, not only in enrolment.
Standards
Systems and training aligned to ICH-GCP, so that domestic trial data is accepted by international regulators and journals without rework.
Independent replication
Confirmation of domestic findings by laboratories with no stake in the result.
Authorship and review
Named authorship, and entry into international peer review, for the investigators who did the work.
Out to the world
Clinical capability
Hospital networks and investigator bases that international science cannot reach on ethical terms any other way.
Governed cohorts
Population-scale data held under national law, analysed without leaving the jurisdiction that governs it.
Under-recognised science
Work already at international standard that has never been routed into international review.
Regional standing
A hub that neighbouring health systems route through, rather than around.
Neither column works without the other. That is the difference between a bridge and a supply chain.
What we bring
Four capabilities, offered without conditions.
Clinical Research Capability
Investigator training, trial design, data governance, and the standards that make a country’s trial data accepted internationally. The objective is a resident capability, not a visiting one.
Capital into Domestic Science
Grants and mission-aligned investment through the NGB Innovation Program, directed at research groups and early-stage companies based in the country. Grants are non-dilutive, and we take no ownership.
A Scientific and Regulatory Bridge
A United States base, scientific leadership, and regulatory literacy, applied so that domestic science can meet international standards and reach international review.
A Flagship Clinical Model
A physician-led longevity center, developed as a working model for precision and preventive medicine that a national program can study and adapt.
Commitments to a host country
The terms are fixed before the conversation starts.
Scientific leadership stays domestic.
Programs are led by investigators at the host country’s own institutions. NGB does not require a lead role as a condition of support.
Intellectual property stays where it originates.
Discoveries made by domestic institutions remain the property of those institutions. NGB takes no equity, royalty, or licensing interest as a condition of a grant.
Data stays under national governance.
Health data remains subject to the host country’s law and the host institution’s governance. NGB does not require transfer of patient-level data abroad.
No implied endorsement.
Support from NGB is not an approval, a validation, or a licence. No organization may present it as one.
No personal benefit.
No founder, director, advisor, employee, or family member may take a financial interest in an opportunity identified through NGB.
None of this is negotiable at the table, because all of it was decided before the table.
How a program is built
Five steps. The last one is leaving.
Define the national priority
We start from the health priorities the country has already set, not from a portfolio we want to place.
Assess existing capability
What research infrastructure, investigator base, and regulatory capacity already exist, and what is genuinely missing.
Design the program jointly
Scope, governance, data rules, intellectual property terms, and success measures agreed in writing before work begins.
Fund and build
Grants, mission-aligned investment, and training directed at the gaps identified, through the documented review process.
Transfer and withdraw
The measure of success is that the capability continues without us.
How we start
The terms are published before the first conversation.
We publish the commitments above before we hold a single national conversation, so that any government evaluating us can hold us to them from the first meeting rather than the last.
Better science.
Stronger systems.
Healthier generations.
A national program should leave a country with more capability than it started with. That is the only outcome we are trying to produce.